Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Silmitasertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 known ✓ | P68400 | 20/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 18/20 | 1.00 |
| ▸ | CSNK2B | P67870 | 18/20 | 1.00 |
| ▸ | CSNK2A3 | Q8NEV1 | 8/20 | 1.00 |
| ▸ | CLK2 | P49760 | 5/20 | 1.00 |
| ▸ | PIM1 | P11309 | 3/20 | 1.00 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 1/20 | 1.00 |
| ▸ | DYRK3 | O43781 | 1/20 | 1.00 |
| ▸ | ULK1 | O75385 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | CCNB2 | O95067 | 1/20 | 1.00 |
| ▸ | CDK1 | P06493 | 1/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 1/20 | 1.00 |
| ▸ | PHKG2 | P15735 | 1/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 1/20 | 1.00 |
| ▸ | CDK2 | P24941 | 1/20 | 1.00 |
| ▸ | TYK2 | P29597 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Silmitasertib SCHEMBL30193004 | 1.00 | CSNK2A1 (1.00) | CSNK2A1CSNK2A2CSNK2BCSNK2A3CLK2 | |
| Silmitasertib SCHEMBL29381056 | 1.00 | CSNK2A1 (1.00) | CSNK2A1CSNK2A2CSNK2BCSNK2A3CLK2 | |
| Silmitasertib SCHEMBL30917987 | 0.99 | CSNK2A1 (0.98) | CSNK2A1CSNK2A2CSNK2BCSNK2A3CLK2 | |
| SCHEMBL30486993 | 0.96 | CSNK2A1 (0.92) | CSNK2A1CSNK2A2CSNK2BCSNK2A3CLK2 | |
| SCHEMBL10134685 | 0.96 | CSNK2A1 (0.92) | CSNK2A1CSNK2A2CSNK2BCSNK2A3CLK2 | |
| SCHEMBL10134643 | 0.93 | CSNK2A1 (1.00) | CSNK2A1CSNK2A2CSNK2BCSNK2A3CLK2 | |
| SCHEMBL2690879 | 0.91 | CSNK2A2 (1.00) | CSNK2A1CSNK2A2CSNK2BCSNK2A3CLK2 | |
| SCHEMBL12232557 | 0.91 | CSNK2A2 (0.83) | CSNK2A1CSNK2A2CSNK2BCSNK2A3CLK2 | |
| SCHEMBL10132079 | 0.90 | CSNK2A2 (0.82) | CSNK2A1CSNK2A2CSNK2BCSNK2A3CLK2 | |
| SCHEMBL28636359 | 0.90 | CSNK2A2 (1.00) | CSNK2A1CSNK2A2CSNK2BCSNK2A3CLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112334133-A | Quinolone analogs and salts thereof, compositions, and methods of use thereof | 生华生物科技股份有限公司 | 2021-02-05 | — | — | CN | claimed |
| EP-3752149-A2 | QUINOLONE ANALOGS AND THEIR SALTS, COMPOSITIONS, AND METHOD FOR THEIR USE | Senhwa Biosciences, Inc. (TW) | 2020-12-23 | — | — | EP | claimed |
| EP-3352794-B1 | COMBINATION OF A PROTEIN KINASE CK2 INHIBITOR AND AN ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE INHIBITOR FOR TREATING RENAL CELL CARCINOMA | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2020-10-14 | — | — | EP | claimed |
| WO-2019168688-A9 | QUINOLONE ANALOGS AND THEIR SALTS, COMPOSITIONS, AND METHOD FOR THEIR USE | SENHWA BIOSCIENCES, INC. (TW) | 2019-11-14 | — | — | WO | claimed |
| US-10322133-B2 | Synthetic lethal drug combination for treating renal cell carcinoma | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2019-06-18 | — | — | US | claimed |
| US-20180256587-A1 | A Synthetic Lethal Drug Combination for Treating Renal Cell Carcinoma | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2018-09-13 | — | — | US | claimed |
| EP-3352794-A1 | A SYNTHETIC LETHAL DRUG COMBINATION FOR TREATING RENAL CELL CARCINOMA | Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) | 2018-08-01 | — | — | EP | claimed |
| US-20170360813-A1 | COMPOSITIONS AND METHODS FOR TREATING MEDULLOBLASTOMA | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2017-12-21 | — | — | US | claimed |
| WO-2017050842-A1 | A SYNTHETIC LETHAL DRUG COMBINATION FOR TREATING RENAL CELL CARCINOMA | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2017-03-30 | — | — | WO | claimed |
| EP-3144014-A1 | A SYNTHETIC LETHAL DRUG COMBINATION FOR TREATING RENAL CELL CARCINOMA | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2017-03-22 | — | — | EP | claimed |
| WO-2025222091-A9 | POLY INFLAMMATORY KINASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS | THE PENN STATE RESEARCH FOUNDATION (US) | 2026-04-30 | — | — | WO | disclosed |
| US-12560609-B2 | Biomarkers predictive of cancer cell response to ML329 or a derivative thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250340848-A1 | METHODS FOR CHEMICAL REPROGRAMMING AND PLURIPOTENT STEM CELLS | PEKING UNIVERSITY (CN) | 2025-11-06 | — | — | US | disclosed |
| EP-4602148-A1 | METHODS FOR CHEMICAL REPROGRAMMING AND PLURIPOTENT STEM CELLS | Peking University (CN) | 2025-08-20 | — | — | EP | disclosed |
| EP-4585273-A2 | MECHANISM OF RESISTANCE TO BET BROMODOMAIN INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-07-16 | — | — | EP | disclosed |
| WO-2009108912-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-09-03 | — | — | WO | disclosed |
| US-20090105233-A1 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-04-23 | — | — | US | disclosed |
| US-20090105233-A1 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-04-23 | — | — | US | disclosed |
| US-20090105233-A1 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-04-23 | — | — | US | disclosed |
| WO-2008028168-A2 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12560609-B2 | Biomarkers predictive of cancer cell response to ML329 or a derivative thereof | KEAP1, NFE2L2, NQO1 | CSNK2A1 1150/4885CSNK2A2 1189/4885CSNK2B 1122/4885 |
| US-20090105233-A1 | SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS | PACSIN2, TNKS, PARP1 | CSNK2A1 24/4885CSNK2A2 37/4885CSNK2B 39/4885 |
| US-20170360813-A1 | COMPOSITIONS AND METHODS FOR TREATING MEDULLOBLASTOMA | CSNK2B, SHH, GLI1 | CSNK2A1 7/4885CSNK2A2 4/4885CSNK2B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.